New Grant of Options

RNS Number : 6793Q

Redx Pharma plc

01 March 2021

 

REDX PHARMA PLC

("Redx" or "the Company" or "Redx Pharma")

New Grant of Options

Alderley Park, 1 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, announces that further to the announcement made on 27 October 2020, Dr Jane Robertson assumed her new role as Chief Medical Officer on 1 March 2021.  

In addition, the Company announces that on 1 March 2021, options over 1,500,000 ordinary shares of 1p each in the share capital of the Company, were granted to Dr Jane Robertson, Chief Medical Officer, under the All employee Share Option scheme, on the following basis:

The options were granted at 66p per share, being the closing price on 26 February 2021.

Name	Position	Number of Options Granted	Vesting Date	Total Options Held Following the Grant
Jane Robertson (PDMR)	Chief Medical Officer	100,000 100,000 100,000 1,200,000	1 March 2022 1 March 2023 1 March 2024 1 March 2024 (subject to performance conditions)	1,500,000

Following the grant referred to above, the Company will have granted options over a total of 31,898,764 Ordinary Shares representing 11.6 per cent. of the share capital in issue. The number of options that may be awarded under the Scheme, and all prior share incentive plans, remains limited such that the aggregate number of Ordinary Shares of 1p each under option will be less than 15 per cent. of the total issued share capital of the Company.

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jane Robertson
2.	Reason for the notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Redx Pharma Plc
b)	LEI	213800HMS4EBXO589Y37
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Options over Ordinary Shares of 1p each
b)	Identification code	ISIN: GB00BSNB6S51
c)	Nature of the transactions	Grant of options under the Redx All Employee Share Option Scheme
d)	Price(s) and volume(s)	Price: 66p pence per share Volume: 1,500,000 shares
e)	Aggregated information -  Aggregated volume -  Price	As for d) above
f)	Date of the transactions	1 March 2021
f)	Place of the transactions	Off-market

For further information, please contact:
Redx Pharma Plc	T: [phone]
Iain Ross, Chairman Lisa Anson, Chief Executive James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)	T: [phone]
Matt Davis/Adam Dawes
WG Partners LLP (Broker)	T: [phone]
Claes Spång/Chris Lee/David Wilson
FTI Consulting	T: [phone]
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

 

END

 

 

DSHKFLBBFXLZBBQ